Colorectal liver metastases

Postgraduate Medical Journal

Volumn 72, Issue 850, 1996, Pages 464-469

  Burke, Dermot ^a   Allen Mersh, Timothy G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases

Indexed keywords

FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CATHETER; COLORECTAL CANCER; DEATH; DIARRHEA; DRUG TOXICITY; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; LIVER TOXICITY; REGIONAL PERFUSION; RISK; SHORT SURVEY; STOMATITIS; TUMOR VOLUME;

EID: 0029739481     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.72.850.464     Document Type: Short Survey

References (53)

1. Office of Population and Census Surveys. Cancer statistics registrations - 1989: Series MBI no 22. London: HMSO Publications, 1994.
2. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastases. Cancer Metastasis Rev 1984; 3: 303-24.
3. Allen-Mersh TG. Improving survival after large bowel cancer. BMJ 1991; 303: 595-6.
4. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumour size, quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 1996; 14: 171-5.
5. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival in patients with colorectal liver metastases treated with continuous hepatic artery fioxuridine by an implanted pump. Lancet 1994; 344: 1255-60.
6. Stangl R, Altendorf-Hofmann A, Chamley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-10.
7. Kemeny MM, Sugarbaker PH, Smith, et al. A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions. Ann Surg 1982; 195: 163-7.
8. Allen-Mersh TG. Serum CEA in the follow up of colorectal carcinoma: experience in a district general hospital. Ann R Coll Surg Eng 1984; 66: 14-6.
9. Kemeny MM, Ganteaume L, Goldberg DA, Hogan JM, Terz JJ. Preoperative staging with computed axial tomography and biochemical laboratory tests in patients with hepatic metastases. Ann Surg 1986; 203: 169-72.
10. Gunven P, Makuuchi M, Takayasu K, et al. Preoperative imaging of liver metastases. Comparison of angiography, CT scan and ultrasonography. Ann Surgery 1985; 202: 537 - 9.
11. Oudkerk M, Van Ooijen B, Man SPM, Tjiam SL, Schmitz PIM, Wiggers T. Liver metastases from colorectal carcinoma: detection with continuous CT angiography. Radiology 1992; 185: 157-61.
12. Dworkin MJ, Burke D, Earlam S, Fordy C, Allen-Mersh TG. Measurement of response to treatment in colorectal liver metastases. Br J Cancer 1995; 71: 873-6.
13. Soyer P, Levesque M, Elias D, Zeitoun G, Roche A. Preoperative assessment of resectability of hepatic metastases from colonic carcinoma: CT portography vs sonography and dynamic CT. AJR 1992; 159: 741-4.
14. Semelka RC, Shoenut JP, Ascher SM, et al. Solitary hepatic metastasis: comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breath-hold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences. J Mag Res Imaging 1994; 4: 319-23.
15. Runge VM, Kirsch JE, Wells JW, Awh MH, Bittner DF, Woolfolk CE. Enhanced liver MR: contrast agents and imaging strategy, [review], Crit Rev Diagn Imaging 1993; 34: 1 -30.
16. Clarke MP, Kane RA, Steele G Jr. Prospective comparison of preoperative imaging and intraoperative ultrasonography (IOUS) in the detection of liver tumours. Br J Surg 1989; 76: 1323-9.
17. Soyer P, Elias D, Zeitoun G, Roche A, Levesque M. Surgical treatment of hepatic metastases: impact of intraoperative sonography. AJR 1993; 160: 511-4.
18. Charnley RM, Morris DL, Dennison AR, et al. Detection of colorectal liver metastases using intraoperative ultrasonography. Br J Surg 1991; 78: 45-8.
19. Olsen AK. Inrraoperative ultrasound and the detection of liver metastases in patients with colorectal cancer. Br J Surg 1990; 77: 998-9.
20. Greenway B. Hepatic metastases from colorectal cancer: resection or not. Br J Surg 1988; 75: 513-9.
21. Leveson LH, Wiggins PA, Giles GR, et al. Deranged liver blood flow patterns in the detection of liver metastases. Br J Surg 1985; 72: 128-30.
22. Hemingway DM, Cooke TG, McCurrach G, et al. Clinical correlation of high activity dynamic hepatic scintigraphy in patients with colorectal cancer. Br J Cancer 1992; 65: 781-2.
23. Leen E, Goldberg JA, Robertson, et al. Detection of hepatic metastases using duplex color Doppler sonography. Ann Surg 1991; 214: 599-604.
24. Attiyeh FF, Streams MW. Second look laparotomy based on CEA elevations in colorectal cancer. Cancer, 1981; 47: 2119-25.
25. Ekberg H, Tranberg K-G, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73: 727-31.
26. Scheele J. Hepatectomy for liver metastases. Er J Surg 1993; 80: 274-6.
27. Vetto JT, Hughes KS, Rosenstein R, Sugarbaker PH. Morbidity and mortality of hepatic resection for metastatic colorectal carcinoma. Dis Colon Rectum 1990; 33: 408-13.
28. Petrelli N, Gupta B, Piedmonte M, Herrera L. Morbidity and survival of liver resection for colorectal carcinoma. Dis Colon Rectum 1991; 34: 899-904.
29. Vaillant J-C, Balladur P, Nordlinger B, et al. Repeat liver reaction for recurrent colorectal metastases. Br J Surg 1993; 80: 340-4.
30. Jiang WG, Hallett MB, Puntis MCA. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis. Br J Surg 1993; 80: 1368-73.
31. Onik G, Rubinsky B, Zemel R, et al. Ultrasoundguided hepatic cryosurgery in the treatment of metastatic colonic carcinoma. Preliminary results. Cancer 1991; 67: 901-7.
32. Masters A, Stegers AC, Lees WR, et al. Interstitial laser hyperthermia: a new approach for treating liver metastases. Br J Cancer 1992; 66: 518-22.
33. Lirraghi T, Vettoni C, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 1991; 179: 709-12.
34. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989; 63: 1036-44.
35. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A: 1658-63.
36. Shimada Y, Yoshima M, Wakui A, et al. Phase II study of CPT-11 a new campotheracin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
37. Kemeny N, Lokich JL, Anderson N, Ahlgren JD. Recent advances in the treatment of advanced colorectal cancer. Cancer 1993; 71: 9-18.
38. Köhner-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM. Chemotherapeutic strategies in metastic colorectal cancer: an overview of current clinical trials. Semin Oncol 1992; 19 (suppl13): 105-25.
39. Kemeny N. The systemic chemotherapy of hepatic metastases. Semin Oncol 1983; 10: 148-58.
40. Poon MA, O'Connell MJ, Moertal CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-17.
41. Glimelius B, Hoffman K, Graf W, Påhlman L, Sjödén P. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
42. Kerr D, Cunningham D, Zalcberg J, et al. 'Tomudex' (ZD1694) has superior response and toxicity profiles compared to 5-fluouracil and leucovorin (5-FU-LV) in advanced colorectal cancer (CRC): first results of a large international phase II study. Br J Cancer 1995; 72 (suppl XXV) 10 (abstract).
43. Levi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluouracil and folinic acid (leucovorin) in patients with colorectal cancer metastasis: a randomised multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
44. Riva P, Marangolo M, Tison V, et al. Treatment of metastastic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine-131: a phase II study. Nucl Med Biol 1991; 18: 109-19.
45. Hennigan TW, Begent RHJ, Allen-Mersh TG. Histamine, leukotriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model. Br J Cancer 1991 ; 6-4: 872-4.
46. Durrant LG, Buckley TJ, Denton GW, Hardcastle JD, Sewell HF, Robins RA. Enhanced cell mediated tumor killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res 1994; 54: 4837-40.
47. Denton GW, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994; 57: 10-4.
48. Folkman J. How is blood growth regulated in normal and neoplastic tissue? - GHA Clowes Memorial Award Lecture. Cancer Res 1986; 46: 467-73.
49. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S. Prevention of hepatic metastases of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995; 55: 836-9.
50. Hawkins MD. Clinical trials of antiangiogenic agents. Curr Opin Oncol 1995; 7: 90-3.
51. Van de Velde CJH, Maurits de Brau L, Sugarbaker PH, Tranberg K-G. Hepatic artery infusion chemotherapy: rationale, results, credits and debits. Reg Cancer Treat 1988; 1: 93-101.
52. Dworkin MJ, Allen-Mersh TG. Regional infusion chemotherapy for colorectal hepatic metastases - where is it going? Cancer Treat Rev 1991; 18: 213-24.
53. Rougier P, Laplanche LA, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomised trial. J Clin Oncol 1992; 10: 1112-8.